30
Participants
Start Date
July 31, 2012
Primary Completion Date
December 31, 2015
Study Completion Date
April 8, 2017
Bendamustine
Bifunctional alkylating agent consisting of a purine and amino acid antagonist (a benzimidazole ring) and an alkylating nitrogen mustard moiety.
Thalidomide
Thalidomide can directly inhibit the growth and survival of myeloma cells, by oxidative damage to DNA mediated by free radicals. The drug can induce apoptosis even in drug resistant myeloma cells. Thalidomide modulates cell adhesion molecule expression, so it may interfere with the mutually stimulatory interactions between myeloma cells and the bone marrow microenvironment.
Dexamethasone
It's a corticosteroid.
Ospedale Civile di Dolo, Dolo
Ospedale dell'Angelo di Mestre, Mestre
Ospedale di Castelfranco Veneto, Castelfranco Veneto
Ospedale Ca Foncello, Treviso
AULSS 2 Feltre, Feltre
Ospedale S. Martino, Belluno
A.O.U S. Maria della Misericordia, Udine
A.O.U Ospedali Riuniti di Trieste Medicina II, Trieste
A.O.U Ospedali Riuniti di Trieste, Trieste
Presidio Ospedaliero di Camposampiero, Camposampiero
A.O di Padova Ematologia e Immunologia Clinica, Padua
A.O di Padova Ematologia, Padua
AULSS 6 Vicenza, Vicenza
Ospedale Policlinico G.B Rossi (Borgo Roma) Ematologia, Verona
Ospedale Policlinico G.B Rossi (Borgo Roma) Medicina II, Verona
Ospedale di Trento - P.O. S. Chiara, Trento
Division of Hematology and CBMT, Bolzano
AULLS 18 di Rovigo, Rovigo
Azienda Ospedaliera Universitaria G. Martino, Messina
Collaborators (1)
Mundipharma Pte Ltd.
INDUSTRY
Azienda Ospedaliera di Bolzano
OTHER